Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies
require multiple dosing and there is an unmet need to develop convenient, safe, and …

Glaucoma is a leading cause of irreversible visual impairment and blindness, affecting over
76.0 million people worldwide in 2020, with a predicted increase to 111.8 million by 2040 …

Microglia are the primary resident retinal macrophages that monitor neuronal activity in real-
time and facilitate angiogenesis during retinal development. In certain retinal diseases, the …

Associating collagen with biodegradable hydrophobic polyesters constitutes a promising
method for the design of medicated biomaterials. Current collagen‐polyester composite …

Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of
irreversible blindness globally and for which intraocular pressure is the only modifiable risk …

This work reports the development of porous poly (ε-caprolactone)(PCL)-based intraocular
implants, prepared by green supercritical carbon dioxide (scCO 2) foaming/mixing method …

Posterior segment disease acts as a major cause of irreversible visual impairments.
Successful treatment of posterior segment disease requires the efficient delivery of …

Vision loss in diabetic retinopathy features damage to the blood–retinal barrier and
neovascularization, with hypertension and the renin–angiotensin system (RAS) having …

Introduction: Considering that the number of patients afflicted by posterior eye diseases is
increasing, effective drug delivery is currently in high clinical demand. Topical administration …

Choroidal neovascularization (CNV) is a major cause of visual impairment in patients
suffering from wet age-related macular degeneration (AMD), particularly when refractory to …